Seres Therapeutics

Rank#10574

Market Cap35.36M

CountryUnited States

Summary

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

History

Seres was founded in 2012 by scientists, venture capitalists and entrepreneurs from Stanford University, Harvard University and MIT. Since then, the company has built an intellectual property portfolio encompassing more than 500 issued and pending patents and applications worldwide. Seres has developed an end-to-end microbiome therapeutic platform that integrates a deep scientific understanding of the biology of the microbiome with a platform to develop and manufacture microbiome therapeutics.

Mission

Seres is committed to unlocking the potential of the human microbiome to treat diseases and improve health.

Vision

Seres envisions a future where microbiome therapeutics enable doctors and patients to personalize patient care and set a new standard of care for diseases that are either inadequately treated, or currently unaddressed.

References

https://in.investing.com/equities/seres-therapeutics-inc

https://finance.yahoo.com/quote/MCRB/profile?p=MCRB

https://www.crunchbase.com/organization/seres-therapeutics

https://sec.report/CIK/0001609809

https://companiesmarketcap.com/

https://www.serestherapeutics.com

Leadership team

Mr. Eric D. Shaff M.B.A. (Pres, CEO & Director)

Mr. David A. Arkowitz M.B.A. (Exec. VP, CFO & Head of Bus. Devel.)

Dr. Matthew R. Henn Ph.D. (Exec. VP & Chief Scientific Officer)

Products / Services